RxDoctor Payments Data

Kelley Hawkins, MD

Ophthalmology · Fresno, CANPI 1790198158

Payments from drug & device makers

$6,264in general payments, 2019–2025

Across 66 payments — averaging $94.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$5K
  • Alcon$451
  • Dompe US, Inc.$363
  • Biotissue Holdings Inc.$142
  • Bausch & Lomb Americas Inc.$125
  • Glaukos Corporation$94
  • plus $325 from 12 others

What the payments were for

  • Consulting fees$4,70875%
  • Food & beverage$1,55625%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,264 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$425,020
Medicare patients
772
Services billed
2,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj15$422,271
RestasisCyclosporine27$40,483
XiidraLifitegrast19$26,148
Prednisolone Acetate758$25,579
BesivanceBesifloxacin Hcl104$23,593
LumiganBimatoprost40$15,516
Cyclosporine18$12,200
Travoprost67$10,420
MieboPerfluorohexyloctane/Pf13$9,717
TyrvayaVarenicline Tartrate14$8,055
Latanoprost401$5,385
ProlensaBromfenac Sodium16$5,198
Loteprednol Etabonate29$5,151
Fluorometholone59$4,517
CombiganBrimonidine Tartrate/Timolol14$4,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$363$422,27115 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$125$35,86432 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Loteprednol Etabonate$43$33,942149 claims
Oyster Point Pharma, Inc.Tyrvaya$49$8,05514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →